The Indian Patent Office has rejected Viiv Healthcare's patent application for the HIV drug, dolutegravir, after nearly a decade of legal battles. This decision opens the market for generic versions, promoting affordable access to treatment and potentially reducing costs. The ruling addresses concerns over 'evergreening' practices in patent filings.
October 16, 2024 at 01:16AM
from Times of India
https://ift.tt/0giV9BD
Patent for HIV drug rejected, paves way for entry of generics
Subscribe to:
Post Comments (Atom)
Is chewing food linked with a long and healthy life?
Chewing food thoroughly is crucial for digestion, nutrient absorption, and overall health. While the ideal number of chews varies, aiming fo...
-
Several notable WWE veterans passed away in 2024, including Sika Anoa'i, Francisco Ciatso, Akebono, Ole Anderson, and Virgil. These wres...
-
A potential collision was averted at Delhi's IGIA when an Indian carrier's A320, arriving from Phuket, slowed down and failed to pro...
-
Horoscope Today: Read daily horoscope predictions for December 7, 2024. Know all about the astrological events and influences that will be a...
No comments:
Post a Comment